Sami-Sabinsa, the globally renowned research-oriented supplier known for its sustainable and innovative nutraceutical and cosmeceutical ingredients, experienced a warm reception of LactoSpore™ Weizmannia coagulans at the Expanding the Lineup: Next Probiotics and Supplement Spring Symposium hosted by the Korean Society for Lactic Acid Bacteria and Probiotics in Seoul, Korea on May 24, 2024. The event, aimed at facilitating knowledge exchange, attracted over 250 guests from the probiotic industry and distinguished speakers from reputed institutes in Korea.

Sami-Sabinsa emphasized the safety and efficacy of its shelf-stable LactoSpore™ Weizmannia coagulans MTCC 5856 at the technical symposium “Expanding the Lineup: Next Probiotics and Supplement” hosted by the Korean Society for Lactic Acid Bacteria and Probiotics at Seoul, Korea, last week.

Dr. Sivakumar Arumugam, Vice President, Biotechnology, Sami-Sabinsa Group, highlighted the features and applications of LactoSpore™, which has been in commercial production for over three decades. Dr. Sivakumar detailed the comprehensive safety and efficacy studies carried out on this versatile probiotic, providing the audience with valuable perspective. In his presentation, Dr. Sivakumar also outlined the different global regulatory approvals that the probiotic LactoSpore™ complies with, including the FDA GRAS, Natural Health Product in Canada by the NNHPD, TGA-Australia, and FSANZ.

High interest in shelf-stable probiotics has made LactoSpore™ a popular ingredient among functional foods and beverage manufacturers in Korea and worldwide. Unlike many other probiotic strains that require refrigeration throughout the supply chain, Weizmannia coagulans stands out due to its natural spore-forming ability and stability in ambient conditions.

For more information, visit www.sabinsa.co.kr

Note: LactoSpore™, a Trademark of Sabinsa Korea Corporation.